Also known as: glucocorticoid
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive effects used across many disease categories. The RAYOS label includes broad uses spanning allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, pulmonary, renal, rheumatologic, infectious, endocrine, neoplastic, and transplant-related conditions. U.S. labeling shows initial approval in 1955.
The FDA approved six cancer therapies in Q2 2026, including first-line sacituzumab govitecan for triple-negative breast cancer and capivasertib for PTEN-deficient prostate cancer. A separate study shows 69% of accelerated-approval cancer drugs need safety updates within 4 years.
A phase IIb trial demonstrated that low-dose IL-2 therapy produced dose-dependent improvements in SLE patients, with 69.7% achieving SRI-4 response at the highest dose versus 23.5% on placebo. A separate systematic review found IL-17 inhibitors remain potential SLE treatment options, though efficacy data are limited.
The FDA has approved three new targeted therapies for different stages of advanced prostate cancer: Truqap for PTEN-deficient tumors, rucaparib for BRCA-mutated castration-resistant disease, and Akeega for BRCA2-mutated castration-sensitive cancer.
Phase 3 trial data show daratumumab reduced relapse risk by 74% in NMOSD. Separately, the FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, with a PDUFA date of August 17, 2026.
PARP inhibitors remain strongest in BRCA1/2-altered tumors as use beyond that group has been uneven. In June 2025, the FDA narrowed Zejula’s first-line ovarian maintenance indication to HRD-positive tumors only.
Obinutuzumab demonstrated superior efficacy in two separate phase 3 trials for systemic lupus erythematosus and primary membranous nephropathy, with statistically significant improvements in remission rates and disease response measures.
Multiple pharmaceutical companies have initiated clinical trials for metastatic castration-resistant prostate cancer in February 2026, with over 180 companies developing 200+ pipeline therapies. Studies include combination therapies and novel drug candidates targeting advanced disease.
Amgen received FDA and European Commission approval for Uplizna to treat generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive, offering twice-yearly maintenance dosing after initial loading doses.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07746245 |
The Efficacy of CAPCT in Patients With PTCL |
NOT_YET_RECRUITING | PHASE2 |
| NCT07724457 |
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07719855 |
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07715734 |
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07714421 |
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients |
NOT_YET_RECRUITING | PHASE1 |
| NCT07712588 |
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07683975 |
Infliximab for Immune Checkpoint Inhibitor Associated AKI |
NOT_YET_RECRUITING | PHASE4 |
| NCT07668895 |
Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07662928 |
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT07654426 |
The CARDIOPROTECT Trial |
RECRUITING | PHASE2 |
